As a growing roster of nations moves to protect individual genomic and other health data in the name of privacy under the General Data Protection Regulation in the EU and similar laws elsewhere, chief aggregators of such data, drug developers, are struggling.
New and updated preclinical and clinical data presented by biopharma firms at the EASL International Liver Congress, including: Antios, Ascletis, Chemomab, Immunocore, Ionis, Mirum.
RSS